Sequoia China leads seed round for next-gen T cell therapy play

RootPath Inc. (Cambridge, Mass.) raised on Aug. 30 $7 million in a seed round led by Sequoia China. Fellow new

Read the full 202 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE